SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    Form 8-K



                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934



      Date of Report (Date of earliest event reported): September 30, 2005


                           Dragon Pharmaceutical, Inc.
             (Exact name of registrant as specified in its charter)


           Florida                      0-27937                65-0142474
           -------                      -------                ----------
(State or other jurisdiction of       (Commission           (I.R.S. Employer
incorporation or organization)        File Number)         Identification No.)



                      1055 West Hastings Street, Suite 1900
                           Vancouver, British Columbia
                                 Canada V6E 2E9
                    (Address of principal executive offices)

                                 (604) 669-8817
                          (Issuer's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Section 5 - Corporate Governance and Management

Item 5.02      Departure  of  Directors  or  Principal  Officers;   Election  of
               Directors; Appointment of Principal Officers.

     (d) On September 30, 2005, the Board of Directors of Dragon  Pharmaceutical
appointed  Mr.  Peter Mak, Mr.  Heinz Frey,  and Mr. Jin Li to the board.  Their
business experience and qualifications are set forth below.

Mr. Peter Mak,  age 44, is a fellow of the  Chartered  Association  of Certified
Accountants  in UK as well as a fellow of the Hong Kong  Institute  of Certified
Public Accountant.  Mr. Mak was formerly the Managing Partner of Arthur Andersen
Southern  China and also a partner of Arthur  Andersen  Worldwide.  Through  his
twenty  years of  accounting  and  financial  practices,  Mr. Mak has  extensive
knowledge and experience in Chinese and international  accounting standards.  In
addition, Mr. Mak is the Chief Financial Officer of New Dragon Asia Corp., whose
shares are registered under the Securities Exchange Act of 1934.

Mr. Heinz Frey, age 67, graduated from University of  Berne/Switzerland in 1966,
has  30  years  of  experience  in  the  telecommunication   industry,  security
manufacturing and service industry. He has broad experience in the management of
various sizes of companies with global  presence,  financing and  controlling of
international  companies,  leading  development,  production,  sales and finance
departments. He is also a board member of various companies.

Mr. Jin Li, age 38, is currently a senior advisor of Phycos  International  Co.,
Ltd. Prior to joining Phycos,  he was a partner at the  international  law firm,
Linklaters.  Mr.  Li  studied  biochemistry  at Peking  University  in China and
received his Master of Science  degree in  Biochemistry  from the  University of
Michigan and his doctoral  degree from Law School of University of Columbia.  He
has more than ten years of experience in  international  IPOs,  M&A and business
transactions.

Concurrent  upon the  appointment of the three new  independent  directors,  the
Board of directors  established an Audit Committee and  Compensation  Committee.
Mr. Peter Mak was elected as the Chairman of Audit Committee with Mr. Heinz Frey
and Mr. Jin Li as members.  Ms.  Xuemei Liu was  elected as the  Chairman of the
Compensation Committee with Dr. Yiukwong Sun and Jin Li as members.

A copy of the press  release  announcing  the naming the three new directors and
their new  committee  assignments  is  included  herewith  as an exhibit to this
report.

Section 9.  Financial Statements and Exhibits.

Item 9.01       Financial Statements and Exhibits

               (c)  Exhibit 99.1

                    Press release dated September 30, 2005.

<PAGE>



                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: October 4, 2005                  Dragon Pharmaceutical, Inc.
                                        a Florida Corporation

                                        /s/ Maggie Deng
                                        ----------------------------------------
                                        Maggie Deng, Chief Operating Officer
[{"type": "8-K", "sequence": "1", "filename": "for093005.txt", "secsgml_size_bytes": 5141}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "051125665"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 30, 2005

                           Dragon Pharmaceutical, Inc.
             (Exact name of registrant as specified in its charter)

           Florida                      0-27937                65-0142474
           -------                      -------                ----------
(State or other jurisdiction of       (Commission           (I.R.S. Employer
incorporation or organization)        File Number)         Identification No.)

                      1055 West Hastings Street, Suite 1900
                           Vancouver, British Columbia
                                 Canada V6E 2E9
                    (Address of principal executive offices)

                                 (604) 669-8817
                          (Issuer's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 5 - Corporate Governance and Management

Item 5.02      Departure  of  Directors  or  Principal  Officers;   Election  of
               Directors; Appointment of Principal Officers.

     (d) On September 30, 2005, the Board of Directors of Dragon  Pharmaceutical
appointed  Mr.  Peter Mak, Mr.  Heinz Frey,  and Mr. Jin Li to the board.  Their
business experience and qualifications are set forth below.

Mr. Peter Mak,  age 44, is a fellow of the  Chartered  Association  of Certified
Accountants  in UK as well as a fellow of the Hong Kong  Institute  of Certified
Public Accountant.  Mr. Mak was formerly the Managing Partner of Arthur Andersen
Southern  China and also a partner of Arthur  Andersen  Worldwide.  Through  his
twenty  years of  accounting  and  financial  practices,  Mr. Mak has  extensive
knowledge and experience in Chinese and international  accounting standards.  In
addition, Mr. Mak is the Chief Financial Officer of New Dragon Asia Corp., whose
shares are registered under the Securities Exchange Act of 1934.

Mr. Heinz Frey, age 67, graduated from University of  Berne/Switzerland in 1966,
has  30  years  of  experience  in  the  telecommunication   industry,  security
manufacturing and service industry. He has broad experience in the management of
various sizes of companies with global  presence,  financing and  controlling of
international  companies,  leading  development,  production,  sales and finance
departments. He is also a board member of various companies.

Mr. Jin Li, age 38, is currently a senior advisor of Phycos  International  Co.,
Ltd. Prior to joining Phycos,  he was a partner at the  international  law firm,
Linklaters.  Mr.  Li  studied  biochemistry  at Peking  University  in China and
received his Master of Science  degree in  Biochemistry  from the  University of
Michigan and his doctoral  degree from Law School of University of Columbia.  He
has more than ten years of experience in  international  IPOs,  M&A and business
transactions.

Concurrent  upon the  appointment of the three new  independent  directors,  the
Board of directors  established an Audit Committee and  Compensation  Committee.
Mr. Peter Mak was elected as the Chairman of Audit Committee with Mr. Heinz Frey
and Mr. Jin Li as members.  Ms.  Xuemei Liu was  elected as the  Chairman of the
Compensation Committee with Dr. Yiukwong Sun and Jin Li as members.

A copy of the press  release  announcing  the naming the three new directors and
their new  committee  assignments  is  included  herewith  as an exhibit to this
report.

Section 9.  Financial Statements and Exhibits.

Item 9.01       Financial Statements and Exhibits

               (c)  Exhibit 99.1

                    Press release dated September 30, 2005.
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: October 4, 2005                  Dragon Pharmaceutical, Inc.
                                        a Florida Corporation

                                        /s/ Maggie Deng
                                        ----------------------------------------
                                        Maggie Deng, Chief Operating Officer